Table 1. Logistic regression analysis for the associations between H19 polymorphisms and neuroblastoma risk.

Genotype	Cases (n=393)	Controls (n=810)	P1	Crude OR (95% CI)	P	Adjusted OR (95% CI)2	P2
rs2839698 (HWE = 0.090)
GG	179 (45.55)	365 (45.06)		1.00		1.00
AG	175 (44.53)	373 (46.05)		0.96 (0.74–1.23)	0.732	0.96 (0.75–1.24)	0.754
AA	39 (9.92)	72 (8.89)		1.11 (0.72–1.70)	0.650	1.11 (0.73–1.71)	0.624
Additive			0.797	1.01 (0.84–1.22)	0.890	1.02 (0.84–1.23)	0.858
Dominant	214 (54.45)	445 (54.94)	0.874	0.98 (0.77–1.25)	0.874	0.99 (0.77–1.26)	0.901
Recessive	354 (90.08)	738 (91.11)	0.561	1.13 (0.75–1.70)	0.561	1.14 (0.75–1.71)	0.541
rs3024270 (HWE = 0.159)
CC	99 (25.19)	213 (26.30)		1.00		1.00
CG	203 (51.65)	424 (52.35)		1.03 (0.77–1.38)	0.842	1.03 (0.77–1.38)	0.829
GG	91 (23.16)	173 (21.36)		1.13 (0.80–1.60)	0.486	1.14 (0.80–1.61)	0.472
Additive			0.764	1.06 (0.89–1.27)	0.494	1.07 (0.89–1.27)	0.480
Dominant	294 (74.81)	597 (73.70)	0.682	1.06 (0.80–1.40)	0.683	1.06 (0.81–1.40)	0.667
Recessive	302 (76.84)	637 (78.64)	0.480	1.11 (0.83–1.48)	0.480	1.11 (0.83–1.48)	0.470
rs217727 (HWE = 0.470)
GG	186 (47.33)	382 (47.16)		1.00		1.00
AG	164 (41.73)	342 (42.22)		0.99 (0.76–1.27)	0.907	0.98 (0.76–1.27)	0.888
AA	43 (10.94)	86 (10.62)		1.03 (0.68–1.54)	0.898	1.02 (0.68–1.53)	0.922
Additive			0.979	1.00 (0.84–1.20)	0.970	1.00 (0.84–1.20)	0.997
Dominant	207 (52.67)	428 (52.84)	0.956	0.99 (0.78–1.26)	0.956	0.99 (0.78–1.26)	0.932
Recessive	350 (89.06)	724 (89.38)	0.865	1.03 (0.70–1.52)	0.864	1.03 (0.70–1.52)	0.884
Combined effect of protective genotypes
0	258 (65.65)	551 (68.02)		1.00		1.00
1-3	135 (34.35)	259 (31.98)	0.410	1.11 (0.86–1.44)	0.410	1.11 (0.86–1.44)	0.411

¹χ² test for genotype distributions between neuroblastoma patients and cancer-free controls.

²Adjusted for age and sex.